ARAVALENT
DEAD

Serial Number

90716789

Owner

Aravalent Therapeutics, Inc.

Attorney

Holly Pranger

Filing Date

May 17, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ARAVALENT Trademark

Serial Number: 90716789

ARAVALENT is a trademark filed by Aravalent Therapeutics, Inc. on May 17, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Aravalent Therapeutics, Inc.

1290 Rancho Conejo Blvd, Suite 101F
Thousand Oaks, CA 91320

Entity Type: 03

Trademark Details

Filing Date

May 17, 2021

Registration Date

Not Registered

Published for Opposition

March 1, 2022

Goods & Services

Pharmaceuticals and medicines for the prevention and treatment of cancer; pharmaceuticals and medicines for the identification and treatment of tumors; pharmaceuticals preparations in the form of capsules, tablets, and powders for the treatment of cancer; intravenous pharmaceuticals, namely, vials for intravenous administration sold filled with preparations for the treatment of cancer; biological preparations for the prevention and treatment of cancer; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in testing and treatment of cancer; medical diagnostic reagents; diagnostic biomarker reagents for medical purposes; pharmaceutical preparations in the nature of drug delivery agents that facilitate administration of other pharmaceutical preparations into the human body for enhanced treatment of cancer

Pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; testing, inspection, research, or development of pharmaceutical preparations for the prevention and treatment of cancer; research and development of pharmaceuticals and medicines for the identification and treatment of tumors; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the fields of pharmaceutical and biological preparations; development of new technology for others in the fields of pharmaceuticals, biotechnology, and medicine; testing of pharmaceuticals; laboratory research services relating to pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical drug development services; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, and diagnostics; biological research and analysis; chemical research; medical research, namely, conducting clinical trials for others

Filing History

ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Apr 18, 2022 MAB5
ABANDONMENT - AFTER PUBLICATION
Apr 18, 2022 ABN5
TEAS EXPRESS ABANDONMENT RECEIVED
Apr 13, 2022 EXAR
EXTENSION OF TIME TO OPPOSE RECEIVED
Mar 30, 2022 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 1, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 1, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 9, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 26, 2022 CNSA
ASSIGNED TO EXAMINER
Jan 25, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 16, 2021 NWOS
NEW APPLICATION ENTERED
May 20, 2021 NWAP